
About Naxpar Group
Naxpar Group is a publicly listed company based in Mumbai (India) founded in 1985 by Prakash Shah and Baiju Shah. Pharmaceutical, cosmetic, herbal, and nutraceutical formulations are manufactured. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. Its Indian entity Parnax Lab Limited reported revenue of βΉ252 Cr. Naxpar Group offers products and services including Pharmaceuticals, Cosmetics, Herbal/Ayurvedic Formulations, and Nutraceuticals. Its focus areas include Pharmaceuticals and Drug Manufacturing.
Company details
Naxpar Group is involved in the development and manufacturing of finished formulations across pharmaceuticals, cosmetics, herbalAyurvedic products, and nutraceuticals. The company operates within the healthcare and personal care sectors, focusing on innovation and quality. Facilities are regularly upgraded to meet international standards, ensuring superior product offerings. Based in India, the group is recognized as a leading manufacturer in these domains, catering to both domestic and global markets with a wide range of solutions.
- Headquarters Mumbai, India
- Founders Prakash Shah, Baiju Shah
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website naxparlab.com
- Social LinkedIn
- Legal Name Parnax Lab Limited
- Market Cap₹132 Cr
PARNAXLAB · NSE
- Share Price₹116.42
+1.66% today
- Revenue₹249 Cr
FY 2025-26 · +32.4% YoY
- EBITDA₹25.88 Cr
Margin 10.4%
- Net Profit₹12.80 Cr
FY 2025-26 · +9.3% YoY
- P/E (TTM)14.5x
P/B 1.3x
- ROE13.2%
ROCE 13.0%
- Debt / Equity0.85
Interest cover 32.0x
Associated legal entities of Naxpar Group
Naxpar Group operates through Parnax Lab Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Parnax Lab Limited Listed CIN L36912MH1982PLC027925 | Active | 03 Aug 1982 | Mumbai, Maharashtra | ₹252 Cr | 9 | View details |
Products & Services of Naxpar Group
Naxpar Group offers a comprehensive portfolio of products and services, including Pharmaceuticals, Cosmetics, Herbal/Ayurvedic Formulations, and Nutraceuticals.
Finished formulations in pharmaceuticals are manufactured and developed.
Cosmetic products are produced for personal care use.
Herbal and Ayurvedic formulations are developed for wellness.
Nutraceutical products are created for dietary health benefits.
Board of directors of Parnax Lab Limited (Naxpar Group)
Parnax Lab Limited is the primary company behind Naxpar Group. The board of Parnax Lab Limited currently have 6 directors; the longest-serving is Ami Mihir Shah, appointed in 2015. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ami Mihir Shah DIN 03101049 | Director | 31 Mar 2015 | 11 yrs 7 mo | Parnax Lab Limited |
| Yogesh Kantilal Varia DIN 09186184 | Director | 28 May 2021 | 5 yrs 5 mo | Parnax Lab Limited |
| Harish Sunderlal Panpalia DIN 10275561 | Director | 11 Aug 2023 | 3 yrs 3 mo | Parnax Lab Limited |
| Mihir Prakash Shah DIN 00387912 | Managing Director | 05 Jul 2024 | 2 yrs 4 mo | Parnax Lab Limited |
| Binoy Baiju Shah DIN 00440880 | Director | 05 Jul 2024 | 2 yrs 4 mo | Parnax Lab Limited |
| Vijaykumar Shivaji Ayare DIN 06383445 | Director | 10 Feb 2025 | 1 yr 9 mo | Parnax Lab Limited |
People of Naxpar Group
2 people are tracked at Naxpar Group (2 in leadership).
| Name | Role | Group |
|---|---|---|
| Co-Founder & Director | Leadership | |
| Co-Founder & Director | Leadership |
Complete people profiles for Naxpar Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Naxpar Group
Naxpar Group is a publicly listed company on the BSE with ticker symbol PARNAXLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jul 2012
- Listed onBSE: 506128
- Listed entityParnax Lab Limited
- Exchange sectorHealth technology
- ISININE383L01019
- Share price₹162.35 (-1.61% on the day) · 2026-05-11
- Market capitalisation₹188 Cr
- Price to earnings14.9
- EPS (diluted, trailing year)₹10.91
- Volume (last session)3,005
- Analyst consensusNo rating
Financials of Naxpar Group
Exchange-reported figures of Parnax Lab Limited, the listed company behind Naxpar Group (NSE: PARNAXLAB).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 249 | 188 | 189 | 168 | 163 | 90.06 | 95.31 |
| Revenue growth | +32.4% | -0.5% | +12.6% | +2.8% | +81.0% | -5.5% | - |
| EBITDA | 25.88 | 26.77 | 23.55 | 22.99 | 23.03 | 9.94 | 6.43 |
| EBITDA margin | +10.4% | +14.3% | +12.5% | +13.7% | +14.1% | +11.0% | +6.8% |
| Profit before tax | 15.90 | 15.68 | 12.06 | 12.28 | 12.26 | (0.09) | (1.97) |
| Net profit | 12.80 | 11.71 | 9.60 | 8.61 | 8.23 | (0.38) | (2.92) |
| Net profit margin | +5.2% | +6.2% | +5.1% | +5.1% | +5.1% | -0.4% | -3.1% |
| EPS (βΉ) | 10.27 | 10.03 | 8.37 | 7.50 | 8.40 | (0.43) | (3.43) |
| Balance sheet | |||||||
| Total assets | 179 | 153 | 153 | 117 | 118 | 91.78 | 84.37 |
| Net worth | 95.14 | 83.10 | 71.58 | 62.16 | 48.18 | 32.54 | 32.79 |
| Total debt | 82.79 | 69.53 | 80.64 | 54.72 | 69.08 | 58.90 | 51.23 |
| Cash & bank | 2.26 | 2.68 | 1.88 | 2.78 | 5.78 | 1.27 | 1.30 |
| Net working capital | 48.20 | 33.72 | 40.69 | 33.66 | 38.56 | 26.63 | 24.51 |
| Cash flow | |||||||
| Cash from operations | 8.00 | 32.30 | 15.88 | 20.91 | 8.55 | 6.31 | 8.75 |
| Cash from investing | (16.39) | (16.39) | (31.52) | (9.92) | (16.50) | (6.56) | (13.33) |
| Cash from financing | 8.18 | (15.82) | 14.82 | (14.07) | 12.13 | 0.05 | 5.03 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 69.26 | 56.80 | 69.63 | 62.94 | 62.60 | 53.38 | 49.04 | 40.22 |
| Revenue growth (YoY) | +10.6% | +6.4% | +42.0% | +56.5% | +29.5% | +6.5% | - | - |
| Other income | 0.21 | 0.15 | 1.99 | 0.97 | 0.63 | 0.18 | 0.43 | 0.19 |
| EBITDA | 6.90 | 4.30 | 4.66 | 5.71 | 8.08 | 7.44 | 6.63 | 4.28 |
| EBITDA margin | +10.0% | +7.6% | +6.7% | +9.1% | +12.9% | +13.9% | +13.5% | +10.6% |
| Depreciation | 2.33 | 2.22 | 2.04 | 1.96 | 2.10 | 1.94 | 1.83 | 1.79 |
| Interest | 1.60 | 1.64 | 1.61 | 1.47 | 1.40 | 1.22 | 1.28 | 1.23 |
| Profit before tax | 3.18 | 0.59 | 3.00 | 3.25 | 5.21 | 4.46 | 3.95 | 1.45 |
| Tax | 0.99 | 0.17 | 0.81 | 0.54 | 1.58 | 1.18 | 1.03 | 0.24 |
| Net profit | 2.19 | 0.42 | 2.19 | 2.71 | 3.63 | 3.28 | 2.92 | 1.21 |
| EPS (βΉ) | 1.90 | 0.37 | 1.90 | 2.37 | 3.15 | 2.85 | 2.55 | 1.06 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 6.63 | 7.02 | 7.44 | 7.47 | 7.15 | 2.37 | 7.68 |
| Revenue growth | -5.6% | -5.7% | -0.4% | +4.5% | +201.7% | -69.1% | - |
| EBITDA | (1.62) | 1.24 | 2.09 | 1.56 | 1.37 | (0.45) | 0.55 |
| EBITDA margin | -24.4% | +17.7% | +28.1% | +20.9% | +19.2% | -19.0% | +7.2% |
| Profit before tax | 0.66 | 1.87 | 2.43 | 1.61 | 0.78 | (1.25) | (0.45) |
| Net profit | 0.93 | 1.41 | 1.81 | 1.19 | 0.54 | (1.13) | (1.99) |
| Net profit margin | +14.0% | +20.1% | +24.3% | +15.9% | +7.6% | -47.7% | -25.9% |
| EPS (βΉ) | 0.77 | 1.21 | 1.59 | 1.05 | 0.55 | (1.33) | (2.36) |
| Balance sheet | |||||||
| Total assets | 23.45 | 22.57 | 21.18 | 20.44 | 21.95 | 16.14 | 16.90 |
| Net worth | 23.42 | 22.55 | 21.16 | 19.36 | 12.75 | 4.71 | 5.82 |
| Total debt | 0.00 | 0.00 | 0.00 | 1.07 | 9.20 | 11.41 | 11.06 |
| Cash & bank | 1.10 | 1.28 | 0.46 | 1.28 | 4.35 | 0.11 | 0.12 |
| Net working capital | 10.83 | 8.96 | 6.96 | 5.57 | 6.58 | 4.18 | 5.18 |
| Cash flow | |||||||
| Cash from operations | (0.72) | 0.28 | 0.08 | (0.28) | (0.36) | 0.47 | 2.20 |
| Cash from investing | 0.57 | (0.19) | 0.30 | 0.14 | 0.00 | 0.00 | (0.01) |
| Cash from financing | (0.03) | (0.02) | (1.21) | (2.92) | 4.59 | (0.48) | (1.55) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.53 | 2.57 | 0.25 | 2.71 | 1.70 | 1.97 | 0.84 | 0.99 |
| Revenue growth (YoY) | -68.8% | +30.5% | -70.2% | +173.7% | +10.4% | -46.2% | - | - |
| Other income | 0.20 | 0.21 | 1.76 | 0.22 | 0.20 | 0.19 | 0.19 | 0.17 |
| Total expenses | 0.86 | 1.91 | 3.27 | 1.96 | 1.20 | 1.81 | 1.12 | 0.92 |
| EBITDA | (0.33) | 0.66 | (3.02) | 0.75 | 0.50 | 0.16 | (0.28) | 0.07 |
| EBITDA margin | -62.3% | +25.7% | -1208.0% | +27.7% | +29.4% | +8.1% | -33.3% | +7.1% |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 |
| Profit before tax | (0.15) | 0.85 | (1.29) | 0.95 | 0.66 | 0.32 | (0.12) | 0.21 |
| Tax | 0.11 | 0.00 | (0.73) | 0.24 | 0.17 | 0.08 | (0.03) | 0.05 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 69.26 | 56.80 | 69.63 | 62.94 | 62.60 | 53.38 | 49.04 | 40.22 |
| Revenue growth (YoY) | +10.6% | +6.4% | +42.0% | +56.5% | +29.5% | +6.5% | - | - |
| Other income | 0.21 | 0.15 | 1.99 | 0.97 | 0.63 | 0.18 | 0.43 | 0.19 |
| EBITDA | 6.90 | 4.30 | 4.66 | 5.71 | 8.08 | 7.44 | 6.63 | 4.28 |
| EBITDA margin | +10.0% | +7.6% | +6.7% | +9.1% | +12.9% | +13.9% | +13.5% | +10.6% |
| Depreciation | 2.33 | 2.22 | 2.04 | 1.96 | 2.10 | 1.94 | 1.83 | 1.79 |
| Interest | 1.60 | 1.64 | 1.61 | 1.47 | 1.40 | 1.22 | 1.28 | 1.23 |
| Profit before tax | 3.18 | 0.59 | 3.00 | 3.25 | 5.21 | 4.46 | 3.95 | 1.45 |
| Tax | 0.99 | 0.17 | 0.81 | 0.54 | 1.58 | 1.18 | 1.03 | 0.24 |
| Net profit | 2.19 | 0.42 | 2.19 | 2.71 | 3.63 | 3.28 | 2.92 | 1.21 |
| EPS (βΉ) | 1.90 | 0.37 | 1.90 | 2.37 | 3.15 | 2.85 | 2.55 | 1.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 249 | 188 | 189 | 168 | 163 | 90.06 | 95.31 |
| Revenue growth | +32.4% | -0.5% | +12.6% | +2.8% | +81.0% | -5.5% | - |
| Other income | 3.78 | 1.68 | 0.82 | 0.77 | 0.33 | 0.21 | 0.66 |
| Total expenses | 223 | 161 | 165 | 145 | 140 | 80.12 | 88.88 |
| Employee cost | 0.00 | 24.43 | 23.72 | 20.05 | 17.43 | 13.68 | 14.08 |
| EBITDA | 25.88 | 26.77 | 23.55 | 22.99 | 23.03 | 9.94 | 6.43 |
| EBITDA margin | +10.4% | +14.3% | +12.5% | +13.7% | +14.1% | +11.0% | +6.8% |
| Depreciation | 8.05 | 7.38 | 6.96 | 6.53 | 5.87 | 5.16 | 4.46 |
| Interest | 5.71 | 5.39 | 5.35 | 4.95 | 5.23 | 5.08 | 4.60 |
| Profit before tax | 15.90 | 15.68 | 12.06 | 12.28 | 12.26 | (0.09) | (1.97) |
| Tax | 4.10 | 4.14 | 2.42 | 3.65 | 4.01 | 0.28 | 0.95 |
| Net profit | 12.80 | 11.71 | 9.60 | 8.61 | 8.23 | (0.38) | (2.92) |
| Net profit margin | +5.2% | +6.2% | +5.1% | +5.1% | +5.1% | -0.4% | -3.1% |
| EPS (βΉ) | 10.27 | 10.03 | 8.37 | 7.50 | 8.40 | (0.43) | (3.43) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.49 | 11.49 | 11.49 | 11.49 | 9.81 | 8.50 | 8.50 |
| Reserves & surplus | 83.65 | 71.61 | 60.09 | 50.67 | 36.55 | 24.04 | 24.29 |
| Shareholders' funds (net worth) | 95.14 | 83.10 | 71.58 | 62.16 | 48.18 | 32.54 | 32.79 |
| Minority interest | 0.16 | 0.14 | 0.12 | 0.11 | 0.09 | 0.08 | 0.07 |
| Secured loans | 45.58 | 28.52 | 38.85 | 22.72 | 27.48 | 21.54 | 29.65 |
| Unsecured loans | 37.21 | 41.01 | 41.79 | 32.00 | 41.60 | 37.36 | 21.58 |
| Total debt | 82.79 | 69.53 | 80.64 | 54.72 | 69.08 | 58.90 | 51.23 |
| Total liabilities | 179 | 153 | 153 | 117 | 118 | 91.78 | 84.37 |
| Assets | |||||||
| Gross block | 161 | 129 | 127 | 108 | 97.25 | 79.40 | 72.73 |
| Net block | 115 | 88.26 | 89.48 | 76.80 | 71.95 | 59.67 | 57.68 |
| Capital work in progress | 11.29 | 29.44 | 20.61 | 2.33 | 3.34 | 4.91 | 2.91 |
| Investments | 0.16 | 0.16 | 0.16 | 0.16 | 0.22 | 0.22 | 0.22 |
| Inventories | 36.22 | 25.77 | 29.93 | 21.69 | 19.93 | 10.79 | 11.15 |
| Sundry debtors | 37.81 | 30.76 | 32.56 | 27.89 | 38.08 | 16.71 | 23.08 |
| Cash & bank balances | 2.26 | 2.68 | 1.88 | 2.78 | 5.78 | 1.27 | 1.30 |
| Loans & advances | 14.39 | 5.56 | 8.94 | 4.96 | 7.24 | 10.47 | 10.08 |
| Total current assets | 90.68 | 64.77 | 73.31 | 57.32 | 71.03 | 39.24 | 45.61 |
| Total current liabilities | 42.48 | 31.05 | 32.62 | 23.66 | 32.47 | 12.61 | 21.10 |
| Net working capital | 48.20 | 33.72 | 40.69 | 33.66 | 38.56 | 26.63 | 24.51 |
| Total assets | 179 | 153 | 153 | 117 | 118 | 91.78 | 84.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.55 | 0.46 | 1.28 | 4.36 | 0.18 | 0.39 | (0.05) |
| Net cash from operating activities | 8.00 | 32.30 | 15.88 | 20.91 | 8.55 | 6.31 | 8.75 |
| Net cash from investing activities | (16.39) | (16.39) | (31.52) | (9.92) | (16.50) | (6.56) | (13.33) |
| Net cash from financing activities | 8.18 | (15.82) | 14.82 | (14.07) | 12.13 | 0.05 | 5.03 |
| Net change in cash | (0.21) | 0.09 | (0.82) | (3.08) | 4.18 | (0.21) | 0.44 |
| Closing cash | 2.26 | 2.68 | 1.88 | 2.78 | 5.78 | 1.27 | 1.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +32.4% | -0.5% | +12.6% | +2.8% | +81.0% | -5.5% | - |
| EBITDA growth | -3.3% | +13.7% | +2.4% | -0.2% | +131.7% | +54.6% | - |
| PBT growth | +1.3% | +30.0% | -1.8% | +0.2% | +9998.0% | +95.4% | - |
| Net income growth | +9.3% | +22.0% | +11.5% | +4.6% | +2265.8% | +87.0% | - |
| Revenue CAGR (3Y) | +14.0% | +4.8% | +28.0% | +20.7% | +14.4% | -5.1% | +0.2% |
| EBITDA CAGR (3Y) | +4.0% | +5.1% | +33.3% | +52.9% | +31.1% | +0.2% | -21.0% |
| Profitability & leverage | |||||||
| Net income margin | +4.7% | +6.2% | +5.1% | +5.2% | +5.1% | -0.4% | -3.1% |
| Return on capital employed | +13.0% | +13.8% | +12.9% | +14.7% | +16.7% | +5.7% | +3.2% |
| Return on net worth | +13.2% | +14.9% | +14.4% | +15.6% | +20.5% | -1.1% | -8.5% |
| Debt / equity | 0.85 | 0.97 | 1.01 | 1.12 | 1.59 | 1.69 | 1.36 |
| Long-term debt / equity | 0.31 | 0.36 | 0.34 | 0.33 | 0.47 | 0.57 | 0.53 |
| Interest cover | 32.04 | 27.80 | 32.25 | 30.07 | 30.48 | 106.28 | 233.50 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.71 | 1.47 | 1.61 | 1.63 | 1.85 | 1.18 | 1.42 |
| Inventory turnover | 8.02 | 6.74 | 7.31 | 8.05 | 10.61 | 8.21 | 9.72 |
| Debtors turnover | 7.25 | 5.93 | 6.24 | 5.08 | 5.95 | 4.53 | 4.51 |
| EPS (βΉ) | 10.25 | 10.03 | 8.37 | 7.50 | 8.40 | (0.43) | (3.43) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 82.83 | 72.35 | 62.32 | 54.11 | 47.24 | 38.26 | 38.56 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.53 | 2.57 | 0.25 | 2.71 | 1.70 | 1.97 | 0.84 | 0.99 |
| Revenue growth (YoY) | -68.8% | +30.5% | -70.2% | +173.7% | +10.4% | -46.2% | - | - |
| Other income | 0.20 | 0.21 | 1.76 | 0.22 | 0.20 | 0.19 | 0.19 | 0.17 |
| Total expenses | 0.86 | 1.91 | 3.27 | 1.96 | 1.20 | 1.81 | 1.12 | 0.92 |
| EBITDA | (0.33) | 0.66 | (3.02) | 0.75 | 0.50 | 0.16 | (0.28) | 0.07 |
| EBITDA margin | -62.3% | +25.7% | -1208.0% | +27.7% | +29.4% | +8.1% | -33.3% | +7.1% |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 |
| Profit before tax | (0.15) | 0.85 | (1.29) | 0.95 | 0.66 | 0.32 | (0.12) | 0.21 |
| Tax | 0.11 | 0.00 | (0.73) | 0.24 | 0.17 | 0.08 | (0.03) | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.63 | 7.02 | 7.44 | 7.47 | 7.15 | 2.37 | 7.68 |
| Revenue growth | -5.6% | -5.7% | -0.4% | +4.5% | +201.7% | -69.1% | - |
| Other income | 2.37 | 0.71 | 0.54 | 0.37 | 0.16 | 0.07 | 0.42 |
| Total expenses | 8.25 | 5.78 | 5.35 | 5.91 | 5.78 | 2.82 | 7.13 |
| Employee cost | 0.00 | 0.90 | 0.74 | 0.55 | 0.52 | 0.45 | 0.51 |
| EBITDA | (1.62) | 1.24 | 2.09 | 1.56 | 1.37 | (0.45) | 0.55 |
| EBITDA margin | -24.4% | +17.7% | +28.1% | +20.9% | +19.2% | -19.0% | +7.2% |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.07 | 0.04 | 0.04 | 0.04 |
| Interest | 0.03 | 0.02 | 0.14 | 0.25 | 0.71 | 0.83 | 1.38 |
| Profit before tax | 0.66 | 1.87 | 2.43 | 1.61 | 0.78 | (1.25) | (0.45) |
| Tax | (0.24) | 0.46 | 0.62 | 0.42 | 0.24 | (0.12) | 1.53 |
| Net profit | 0.93 | 1.41 | 1.81 | 1.19 | 0.54 | (1.13) | (1.99) |
| Net profit margin | +14.0% | +20.1% | +24.3% | +15.9% | +7.6% | -47.7% | -25.9% |
| EPS (βΉ) | 0.77 | 1.21 | 1.59 | 1.05 | 0.55 | (1.33) | (2.36) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.49 | 11.49 | 11.49 | 11.49 | 9.81 | 8.50 | 8.50 |
| Reserves & surplus | 11.93 | 11.06 | 9.67 | 7.87 | 1.12 | (3.79) | (2.68) |
| Shareholders' funds (net worth) | 23.42 | 22.55 | 21.16 | 19.36 | 12.75 | 4.71 | 5.82 |
| Secured loans | 0.00 | 0.00 | 0.00 | 1.07 | 1.89 | 2.63 | 2.77 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 7.31 | 8.78 | 8.29 |
| Total debt | 0.00 | 0.00 | 0.00 | 1.07 | 9.20 | 11.41 | 11.06 |
| Total liabilities | 23.45 | 22.57 | 21.18 | 20.44 | 21.95 | 16.14 | 16.90 |
| Assets | |||||||
| Gross block | 1.08 | 1.05 | 1.05 | 0.92 | 0.87 | 0.87 | 0.87 |
| Net block | 0.39 | 0.43 | 0.49 | 0.43 | 0.44 | 0.48 | 0.53 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 10.03 | 10.03 | 10.03 | 10.03 | 10.07 | 10.07 | 10.07 |
| Inventories | 0.80 | 0.78 | 0.90 | 0.58 | 0.79 | 0.58 | 0.15 |
| Sundry debtors | 0.42 | 0.85 | 0.59 | 1.08 | 1.86 | 0.43 | 2.06 |
| Cash & bank balances | 1.10 | 1.28 | 0.46 | 1.28 | 4.35 | 0.11 | 0.12 |
| Loans & advances | 9.51 | 7.79 | 6.08 | 3.56 | 1.16 | 4.56 | 4.60 |
| Total current assets | 11.83 | 10.70 | 8.03 | 6.50 | 8.16 | 5.68 | 6.93 |
| Total current liabilities | 1.00 | 1.74 | 1.07 | 0.93 | 1.58 | 1.50 | 1.75 |
| Net working capital | 10.83 | 8.96 | 6.96 | 5.57 | 6.58 | 4.18 | 5.18 |
| Total assets | 23.45 | 22.57 | 21.18 | 20.44 | 21.95 | 16.14 | 16.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.50 | 0.44 | 1.27 | 4.33 | 0.10 | 0.11 | (0.53) |
| Net cash from operating activities | (0.72) | 0.28 | 0.08 | (0.28) | (0.36) | 0.47 | 2.20 |
| Net cash from investing activities | 0.57 | (0.19) | 0.30 | 0.14 | 0.00 | 0.00 | (0.01) |
| Net cash from financing activities | (0.03) | (0.02) | (1.21) | (2.92) | 4.59 | (0.48) | (1.55) |
| Net change in cash | (0.18) | 0.06 | (0.83) | (3.07) | 4.23 | (0.01) | 0.64 |
| Closing cash | 1.10 | 1.28 | 0.46 | 1.28 | 4.35 | 0.11 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -5.6% | -5.7% | -0.4% | +4.5% | +201.7% | -69.1% | - |
| EBITDA growth | -230.7% | -40.7% | +34.0% | +13.9% | +404.4% | -181.8% | - |
| PBT growth | -64.9% | -22.6% | +50.9% | +106.4% | +9998.0% | -177.8% | +13.5% |
| Net income growth | -34.0% | -22.1% | +52.1% | +120.4% | +147.8% | +43.2% | - |
| Revenue CAGR (3Y) | -3.9% | -0.6% | +46.4% | -0.9% | +3.3% | -25.8% | +13.3% |
| EBITDA CAGR (3Y) | - | -3.0% | - | +41.6% | +139.3% | -26.0% | -4.9% |
| Profitability & leverage | |||||||
| Net income margin | +13.6% | +20.2% | +24.3% | +15.9% | +7.6% | -47.7% | -25.8% |
| Return on capital employed | +2.4% | +6.7% | +9.1% | +6.2% | +6.2% | 0.0% | 0.0% |
| Return on net worth | +3.2% | +5.0% | +6.5% | +4.8% | +4.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.03 | 0.32 | 1.18 | 2.13 | 1.63 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.17 | 0.44 | 0.42 |
| Interest cover | -1.79 | 1.68 | 6.90 | 16.78 | 53.38 | -169.39 | 270.59 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 6.23 | 6.69 | 7.55 | 8.35 | 8.22 | 2.72 | 8.83 |
| Inventory turnover | 8.39 | 8.36 | 10.05 | 10.91 | 10.44 | 6.49 | 26.95 |
| Debtors turnover | 10.44 | 9.75 | 8.91 | 5.08 | 6.24 | 1.90 | 3.37 |
| EPS (βΉ) | 0.77 | 1.21 | 1.59 | 1.05 | 0.55 | (1.33) | (2.36) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 20.39 | 19.63 | 18.42 | 16.85 | 11.14 | 5.54 | 6.85 |
Web traffic of Naxpar Group
Websites that share an audience with Naxpar Group (naxparlab.com).
Websites whose visitors overlap most with Naxpar Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.co.in | 100% | 77M | #407 | View details | |
| mangalamdrugs.com | 95% | 9.9K | #1,747,627 | View details | |
salvuspharma.in | salvuspharma.in | 91% | #1,994,124 | β | |
astermedipharm.in | astermedipharm.in | 90% | #9,642,018 | β | |
| calyxindia.com | 87% | 1K | #7,901,342 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Naxpar Group
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Naxpar Group (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Naxpar Group
Complete news archive for Naxpar Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Naxpar Group
Naxpar Group was founded in 1985.
Naxpar Group is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
The primary company behind Naxpar Group, Parnax Lab Limited, reported revenue of βΉ252 Cr for FY 2026, up 32% year on year.
Naxpar Group is involved in the development and manufacturing of finished formulations across pharmaceuticals, cosmetics, herbalAyurvedic products, and nutraceuticals. The company operates within the healthcare and personal care sectors, focusing on innovation and quality. Facilities are regularly upgraded to meet international standards, ensuring superior product offerings. Based in India, the group is recognized as a leading manufacturer in these domains, catering to both domestic and global markets with a wide range of solutions.
Naxpar Group offers Pharmaceuticals, Cosmetics, Herbal/Ayurvedic Formulations, and Nutraceuticals.
Yes, Naxpar Group is publicly traded on BSE under the ticker symbol PARNAXLAB.
Naxpar Group operates through Parnax Lab Limited.
The legal entities of Naxpar Group currently have 7 directors, including Ami Mihir Shah, Yogesh Kantilal Varia, Preet Vijay Kukreja and others.
